中山严重痔疮症状(中山痔疮的治疗费用多少) (今日更新中)

The captain of a duck boat that capsized in July on a Missouri lake, killing 17 people, has been indicted by a federal grand jury in connection with the wreck.Kenneth Scott McKee, 51, faces 17 counts related to "acts of misconduct, negligence or inattention to duty," one for each victim, according to the indictment, which was announced Thursday by the US Attorney for the Western District of Missouri, Tim Garrison.The violations are colloquially known as "seaman's manslaughter," Garrison said.A federal grand jury found that McKee failed to properly assess incoming weather before and while he put the vessel in the water, entered the vessel on the water as severe weather approached, failed to instruct passengers to put on personal flotation devices and operated the duck boat in violation of its conditions and limitations, among other acts, according to the indictment.The federal criminal investigation into the deadly wreck on Table Rock Lake, near the tourist hub of Branson, Missouri, began after the US Coast Guard in July determined the deaths resulted from the captain's actions. The investigation is ongoing, Garrison told reporters Thursday.Ripley Entertainment, which runs the duck boat tours called Ride the Ducks Branson, did not immediately respond Thursday CNN's requests for comment. McKee's attorney, J.R. Hobbs, confirmed to CNN he is reviewing the indictment against his client but is not making any additional comment regarding the allegations.McKee is not in custody, Garrison said, adding that the charges announced Thursday are the first criminal indictments related to the incident. The US attorney would not say whether McKee has been cooperating with the probe. Hobbs said he is in the process of scheduling an initial court appearance by McKee.Survivor Tia Coleman, whose husband, three children and five other relatives were killed in the duck boat wreck, commended Garrison as the indictments were announced."While nothing can ever ease the grief in my heart, I am grateful that the US Attorney's Office is fighting for justice for my family, and the other victims, and is committed to holding fully accountable all those responsible for this tragedy," she said in a statement.In case of a conviction, each count against McKee carries possible prison time of up to 10 years and a fine of as much as 0,000. 2352

The first vote of my life We are here to serve We pray for every servant leader in the world ?? pic.twitter.com/UWSrKslCt1— ye (@kanyewest) November 3, 2020 178

The family of Pfc. Vanessa Guillen, an Army soldier who was allegedly killed by a fellow soldier and his girlfriend, met with President Donald Trump on Thursday.Guillen's family began the day with a morning march on the National Mall in support of a military-focus sexual harassment bill bearing her name. The family and their attorney later met with the President at the White House.The event was closed to the press."It hit me very hard," Trump said later Tuesday about meeting with Guillen's family, according to CBS News. "We didn't want this to be swept under the rug."Guillen was last seen on April 22 at Fort Hood, Texas, where she had been stationed. On June 30, Guillen's dismembered remains were found on the banks of a nearby river.Hours later, a suspect in the case, Spc. Aaron Robinson died by suicide during a standoff with police. Robinson's girlfriend, Cecily Ann Aguilar, was later charged with assisting in hiding Guillen's body. Aguilar has pleaded not guilty.Guillen's family maintains that she had been sexually harassed by Robinson and others prior to her disappearance. They claim she did not report the abuse to her superior officers because she feared retribution.While an investigation into sexual harassment against Guillen remains open, the Army has not yet confirmed the family's claims. According to ABC News, the Army has confirmed that Guillen may have been harassed, but it was not of a sexual nature.The bill for which Guillen's family was marching, the #IAmVanessaGuillen Bill, would allow military members to file harassment claims with third-party agencies instead of within their chain of command."We will not accept anything less than justice for Vanessa," Attorney Natalie Khawam said, according to KPRC-TV in Houston. "When someone volunteers to serve our country, they deserve to be treated with dignity and respect by their fellow service members. This bill will help us provide the protection and respect to others that was denied to Vanessa." 1995

The federal government has placed thousands of unaccompanied immigrant children in the homes of sponsors, but last year it couldn't account for nearly 1,500 of them.Steven Wagner, a top official with the Department of Health and Human Services, disclosed the number to a Senate subcommittee last month while discussing the state of the Office of Refugee Resettlement (ORR) that oversees the care of unaccompanied immigrant children.Wagner is the acting assistant secretary for the Administration for Children and Families, which is part of the Department of Health and Human Services. ORR is a program of the Administration for Children and Families.CNN reported earlier this month that, in his testimony, Wagner said during the last three months of 2017, the ORR lost track of nearly 1,500 immigrant children it had placed in the homes of sponsors.Wagner's statement has attracted more attention amid reports that immigrant children are being separated from their parents at the US border. 998

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concerns that not enough was known about the drug's risks.In response to questioning at a budget hearing last week, FDA Commissioner Scott Gottlieb told members of Congress that he would "take another look" at Nuplazid, which is the only drug approved to treat hallucinations and delusions associated with Parkinson's disease psychosis.The medication has been cited as a so-called "suspect" medication in hundreds of deaths voluntarily reported by caregivers, doctors and other medical professionals since it hit the market, as highlighted in a recent CNN report.The FDA told CNN this week that the agency had already begun conducting a new evaluation of the medication when Gottlieb was questioned about it at the hearing. The agency said the review had started several weeks ago."What does it take for a drug like this to be taken off the market?" asked US Rep. Rosa DeLauro, a member and former chair of the congressional subcommittee responsible for funding and overseeing the FDA.DeLauro pressed Gottlieb for answers on his agency's response to the safety concerns surrounding Nuplazid."How many more adverse events do we have to have reported? How many people, quite frankly, have to die? Why does the industry always take precedence over public health and safety?"Tracked by the FDA, the adverse event reports cited by DeLauro do not mean that a suspected medication has been ruled the cause of harm and are typically not the result of official investigations. But the FDA uses the information to monitor potential issues with a drug and can take action as needed: updating a medication's label, for instance, or restricting its use. In rare cases, the agency can even pull a drug off the market.When asked by CNN about what prompted the FDA's new evaluation of Nuplazid, the agency said the decision was based on a number of factors but wouldn't say what those factors were. Instead, it would only comment generally, saying that it identifies "potential signals of serious risk/new safety information" in part by using adverse event data and that the agency is not suggesting physicians stop prescribing the drug or take patients off of it while a safety evaluation is taking place.The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.But physicians, researchers and other medical experts told CNN that the high number of reports deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.Nuplazid's review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.Dr. Paul Andreason, the physician who led the FDA's medical review of Nuplazid, warned that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.At that advisory committee meeting two years ago, one woman said that her grandmother had been part of the clinical trials for the drug and that Nuplazid had been life-changing."We didn't know what to expect or even if she was on the drug" or a placebo, said Zoey Wade. "We soon realized that she must be taking the drug, because she really returned to herself. Her hallucinations reduced, and she better understood what was real and what was imaginary."Shortly after Nuplazid's release, however, patients' family members, doctors and other health care professionals started reporting "adverse events" possibly linked to the medication -- including deaths, life-threatening incidents, falls, insomnia, nausea and fatigue.During the first 10 months Nuplazid was on the market, 244 deaths were reported to the FDA in which Nuplazid was a "suspect" medication, according to an analysis conducted by the Institute for Safe Medication Practices. FDA data now show that the number of reported deaths has risen to more than 700. In more than 1,000 reports, patients continued to experience hallucinations while on Nuplazid.After CNN published its investigation on Nuplazid, reporters were contacted by family members who said the drug helped tame hallucinations with few apparent side effects and others who said they believe Nuplazid contributed to their family member's decline or death. Some said they had not yet reported these experiences to the drugmaker or the FDA.While the FDA has long been criticized for being too slow to approve drugs, DeLauro seized on its push to streamline the process, lambasting the agency for putting industry interests and efficiency above public health and safety.DeLauro described the number of adverse events and deaths as "staggering" and "unprecedented." She also expressed concern that the drugmaker, Acadia Pharmaceuticals, is attempting to get the drug approved for a larger population: patients who suffer from dementia-related psychosis."I don't know why it should stay on the market, especially when the FDA has not determined it to be safe and while the number of adverse events continues to soar," she told Gottlieb.In response to the congresswoman's remarks, Acadia told CNN that adverse event data alone are "not a comprehensive and accurate indicator of the safety profile of any drug." In response to CNN's earlier report on the drug, Acadia said there are a number of reasons for the higher volume of death reports, including the fact that the company distributes Nuplazid through a network of specialty pharmacies that puts the company in more frequent contact with both patients and caregivers -- meaning Acadia is more likely to receive reports of death, which it is required to pass along to the FDA.Commissioner Gottlieb told the committee that the FDA is careful about the decisions it makes and that there may be a higher tolerance for risk in situations where there is an unmet medical need, "so long as the patient is properly informed of what those risks are." This echoed what he told CNN's Dr. Sanjay Gupta in an interview earlier this month.The FDA previously told CNN that it was aware of Nuplazid's "complex safety profile" at the time of approval and required the drugmaker to place warnings on its labeling. The agency also said that, though it was continuing to monitor available information about Nuplazid, it had "not identified a specific safety issue" not already reflected on the medication's label.DeLauro's office told CNN that it plans to follow up with the FDA about its inquiry into Nuplazid. 7224

来源：资阳报